BioNTech AG (Biopharmaceutical New Technologies, Mainz, Germany) develops innovative therapeutics and biomarker-based diagnostics. The company, founded in 2008, is the result of years of pioneering research and groundbreaking achievements.
BioNTech’s initial three digit million first-round financing was among the largest initial financing rounds in the history of the biopharmaceutical sector. BioNTech AG is a holding company; together with its subsidiaries, the company offers a spectrum of competencies, innovations and products under one strategic umbrella.
We envision building a next-generation biopharmaceutical company that develops precisely targeted, highly effective, and well-tolerated therapies tailored for individual patients. Our core focus is personalized oncology therapy.
An der Goldgrube 12